Wire · regulatory
FDA delays abortion pill safety study results, retaining telehealth prescriptions
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 10 October 2026 · Fusion42 review
The FDA has postponed the release of a safety study on the abortion pill mifepristone until possibly March 2027, maintaining current telehealth prescription access despite lawsuits challenging the drug's safety. This delays potential regulatory changes impacting telehealth prescriptions and abortion medication access.
This Wire brief sits within Fusion42's coverage of Health, and 2 sources have reported it.
◆ ◆ The Wire takeaway
You face a prolonged regulatory pause keeping telehealth abortion pill prescriptions intact through at least 2027. Reassess your telehealth and medication abortion strategies as market access remains stable but regulatory risk lingers.
◆ Coverage
2 sources · 8 Oct 2026
◆ Related on Wire
◆ Topics